You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Small blood pumps for small patients

    SBC: Vadovations, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant Heart failure and congenital heart defects threaten the lives of several thousand children each year The only FDA approved long term pediatric heart support device is the Berlin Heart Excor which is based on year old technology and is fraught with complications including blood clots forming in the device requiring frequent device replacement The recipien ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea

    SBC: SELEXYS PHARMACEUTICALS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle cell disease. P-selectin mediates the first step in the recruitment of white blood cells to sites of inflammation. Vasoocclusion is precipitated by a P- selectin-mediated adhesion of sickled red ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  3. Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease

    SBC: SELEXYS PHARMACEUTICALS CORPORATION            Topic: NIDDK

    DESCRIPTION (provided by applicant): The primary objective of this proposal is to develop and commercialize a safe and more effective therapy for the treatment of Crohn's Disease, an inflammatory bowel disease. Crohn's Disease is a chronic inflammatory disorder of the gastrointestinal tract that affects some 500,000 patients in the US. Selexys Pharmaceuticals is developing a fully human anti-PSGL- ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea

    SBC: SELEXYS PHARMACEUTICALS CORPORATION            Topic: NHLBI

    DESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug called SelG1 directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle cell disease. The ultimate goal of this Phase IIB proposal is to further advance SelG1 into Phase II/III safety and efficacy trials to support of regulatory filings for FDA approval ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Miniature Right Heart Support Device

    SBC: Vadovations, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Congestive heart failure (CHF) is one of the most serious medical challenges of our day. With 5 million Americans compromised by the ravages of this disabling disease, CHF is the leading cause of Medicare hospital admissions. The economic burden exceeds 40 billion annually. A comprehensive approach to this ominous healthcare threat includes prevention and earl ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Graphical Indes for Aircraft Legacy Data

    SBC: Anautics, Inc.            Topic: AF03274

    This model-centric approach must integrate different model types with simulation, surrogates, systems and components at different levels of abstraction and fidelity across disciplines throughout the life cycle. The integrated perspectives provide cross-domain views for rapid system level analysis allowing engineering from various disciplines and using dynamic models and surrogates to enable contin ...

    SBIR Phase II 2020 Department of DefenseAir Force
  7. Safety and Toxicology Studies of CLT-005 as a Therapeutic for Diabetic Macular Ed

    SBC: Charlesson, LLC            Topic: NEI

    DESCRIPTION (provided by applicant): The objective of this proposal is to finalize development of CLT-005, a novel small molecule inhibitor of Stat3, through the performance of studies required for the submission of an investigative new drug application with the US Food and Drug Administration (FDA). Activation of the Stat3 pathway in retinal inflammatory and angiogenic diseases has been obser ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease

    SBC: SELEXYS PHARMACEUTICALS CORPORATION            Topic: NIDDK

    DESCRIPTION (provided by applicant): The primary objective of this proposal is to develop and commercialize a safe and more effective therapy for the treatment of Crohn's Disease, an inflammatory bowel disease. Crohn's Disease is a chronic inflammatory disorder of the gastrointestinal tract that affects some 500,000 patients in the US. Selexys Pharmaceuticals is developing a fully human ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Biosensor for Detecting Antibiotic Resistance

    SBC: Nomadics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Antibacterial resistant Staphylococcus aureus, in particular methicillin-resistant S. aureus (MRSA), infections constitute a serious worldwide health problem. MRSA infections are usually hospital-acquired, although the

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Monoclonal Antibodies to Treat Pancreatic Cancer

    SBC: COARE BIOTECHNOLOGY, INC.            Topic: NCI

    Abstract Pancreatic ductal adenocarcinoma PDAC is a devastating cancer with an extremely low year survival rate even for those who are diagnosed early Novel research suggests that this may be the result of metastatic dissemination preceding or concurrent to the development of the primary tumor Epithelial mesenchymal transition EMT is one of the key pathways in pancreatic cancer invasion ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government